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INTRODUCTION 
Hepatitis C virus (HCV) infection causes chronic hepatitis in 
most patients, and some of them eventually develop cirrhosis or 
hepatocellular carcinoma.1 It is estimated that approximately 3% 
of the world’s population are infected with HCV and chronic hep-
atitis C (CHC) accounts for about 15–20% of all chronic liver dis-
ease in South Korea.  Transmission of HCV is parenteral, and the 
major transmission routes include drug abuse, insecure injections 
or medical procedures, contaminated syringes or needles, sexual 
contact with an HCV-infected person, vertical infection of new-
borns by infected mothers, the transfusion of blood or blood 
products contaminated with viruses, and organ transplants.2 Be-
tween 2015 and 2016, mass outbreaks of HCV occurred at several 
hospitals in Seoul and other provincial clinics, primarily due to re-
use of disposable syringes. 
As an effective HCV vaccine has not yet been discovered, public 
health considerations underscore the need to develop both an un-
derstanding of the national epidemiology of HCV infection and a 
preventive strategy to block routes of this condition.
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Chronic hepatitis C (CHC) is caused by hepatitis C virus (HCV) infection. HCV infection causes acute hepatitis, and 
the majority of those infected progress to chronic hepatitis, and some of them develop cirrhosis and hepatocellular 
carcinoma. Transmission of HCV is parenteral, and the major transmission routes include drug abuse, insecure injections 
or medical procedures, contaminated syringes or needles, sexual contact with an HCV-infected person, vertical 
infection of newborns by infected mothers, the transfusion of blood or blood products contaminated with viruses, and 
organ transplants. As no vaccine against HCV is available, HCV management involves  blocking routes of transmission 
transmission, screening for HCV infection, and protecting liver disease progression by treatment. Highly potent oral 
direct antiviral agents are now available. Therefore, early detection through nation-wide screening program and 
appropriate treatment should be implemented to improve the quality of life of patients with HCV. Furthermore, for 
the effective HCV control in South  Korea, The organization of an ‘integrated national viral hepatitis control system’ is 
desirable. (Clin Mol Hepatol 2017;23:212-218)
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EPIDEMIOLOGY
Routes of transmission
Transmission of HCV is parenteral, and a screening test for 
blood donors was introduced in 1991. Therefore, transmission via 
transfusion was not a major route of infection after 1992.3-5 The 
use of illicit drugs is a well-known risk factor for HCV infection; 
indeed, the proportion of HCV infection among drug users is ap-
proximately 80% in South Korea.5,6 However, a nationwide pro-
spective cohort study that included 1,173 subjects revealed that 
the proportion of drug abuse was 5%.7 Thus, identification of 
other routes of transmission is necessary. According to a study of 
207 patients with chronic HCV infection, the risk factors for HCV 
infection include older age, needle-stick injury, dental proce-
dures,  multiple sex partners (≥4), blood transfusion before 1991, 
and surgery.8 A comparative study of 1,173 HCV patients and 534 
controls in five university hospitals between 2007 and 2011 in 
South Korea reported several independent risk factors for infec-
tion, including use of illicit drugs, needle-stick injury, transfusion 
before 1995, tattoo, and age.7
Prevalence in adult health-check examinees
The estimated age-standardized prevalence of anti-HCV in adult 
health-check examinees > 40 years of age is 1.29% (95% confi-
dence interval, 1.12–1.48) according to a collective study of 
health-check examinees from Seoul, Ulsan, Jeollanam-do, and 
Daegu between 1995 and 2000.6,9-12 In 2009, the prevalence of 
anti-HCV was 0.78% in 291,314 patients older than 20 years who 
underwent health check-up at 29 health examination centers using 
the 3rd generation enzyme immunoassay (EIA) after adjusting for 
age, sex, and area. In that study, the prevalence of anti-HCV was 
higher in females (0.83%) than in males (0.75%) and increased 
with age (20–29 years, 0.34%; 30–39 years, 0.41%; 40–49 
years, 0.60%; 50–59 years, 0.80%; 60–69 years, 1.53%; and ≥
70 years, 2.31%).3 Additionally, the anti-HCV prevalence varied 
geographically; in comparison with the prevalence of 0.50–1.20% 
in most regions, including Seoul and Gyeonggi-do, the prevalence 
in Pusan and Jeollanam-do were 1.53% and 2.07%, respectively. 
The Jeju Special Self-Governing Province had the lowest preva-
lence, 0.23% (Fig. 1).3
The Korea National Health and Nutrition Examination Survey 
has included anti-HCV testing since 2012. From 2012 to 2014, the 
prevalence of hepatitis C antibody positivity was 0.7% among 
15,795 subjects aged ≥19 years, which was similar to that in the 
2009 National Health Survey (Table 1). The prevalence was low 
(0.4%) in subjects with a high level of income.13
According to the infectious disease statistics of the Korea Cen-
ter for Disease Control,14 the average number of reports of hepati-
tis C infection in 2015 was 4,205 (standard deviation, 331.1). Up 
to the end of August 2016, 4,003 cases had been reported; there-
fore, the number of reports has increased within the past 2 years 
(Table 2). However, according to the 2014 annual surveillance re-
port of the Korea Center for Disease Control,15 the number of re-
ports per institution has remained relatively stable, at 43.2 in 
2011 and 35 in 2014 (Fig. 2).
Prevalence of anti-HCV in high-risk groups
High-risk groups for HCV infection include people who inject 
drugs, patients under hemodialysis, and those with human immu-
nodeficiency virus (HIV) infection, hemophilia, and leprosy. How-
ever, the majority of studies of the prevalence of HCV in these 
groups were conducted prior to 2000; few studies were per-
formed thereafter.2
According to a 1997 survey, the domestic anti-HCV prevalence 
among intravenous drug users was 79.2%.16 From 2007 to 2010, 
the rates of hepatitis C antibody positivity and HCV ribonucleic 
acid (RNA) positivity among the HCV RNA-positive subjects 
Figure 1. Map of South Korea showing age and sex-adjusted anti-HCV 
seroprevalence in each area.3
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among 318 intravenous drug abusers in South Korea were 48.4% 
and 98.1%, respectively.17 The anti-HCV prevalence was 5.9–
14.7% in previous studies of >200 patients with chronic kidney 
disease who underwent hemodialysis between 1997 and 
1998.18,19 According to the 2014 report of the Korean Society of 
Nephrology,20 the hepatitis C antibody positivity rate was 2.2% 
and was correlated with the duration of hemodialysis. The co-in-
fection of HCV and HIV was relatively high, which accounts for 
5.0-6.3% of HIV infected patients in South Korea.21-23 According 
to a 2002 report, the anti-HCV prevalence in hemophilia patients 
was 42.3%, and the risk of infection was correlated with age and 
Table 1. The prevalence of hepatitis C antibody positivity from the Korea National Health and Nutrition Examination Survey for the period from 2012 
to 2014 from the Korea National Health and Nutrition Examination Survey (unit: %)
n
Prevalence 
(standardized error)
n
Prevalence 
(standardized error)
n
Prevalence 
(standardized error)
≥19 years old 15,795 0.7 (0.1) 6,806 0.6 (0.1) 8,989 0.8 (0.1)
≥30 years old 13,915 0.8 (0.1) 6,011 0.7 (0.1) 7,904 0.9 (0.1)
Age (years)
10-18 1,969 0.1 (0.1) 1,045 0.1 (0.1) 924 0.1 (0.1)
19-29 1,880 0.2 (0.1) 795 0.1 (0.1) 1,085 0.3 (0.2)
30-39 2,818 0.3 (0.1) 1,208 0.2 (0.1) 1,610 0.3 (0.2)
40-49 2,955 0.5 (0.2) 1,287 0.6 (0.3) 1,668 0.5 (0.2)
50-59 3,125 0.9 (0.2) 1,302 0.8 (0.2) 1,823 1.0 (0.3)
60-69 2,729 1.3 (0.2) 1,234 1.2 (0.3) 1,495 1.3 (0.3)
70+ 2,288 1.9 (0.4) 980 1.4 (0.4) 1,308 2.2 (0.5)
Residence (standardized)
Dong 14,347 0.5 (0.1) 6,273 0.4 (0.1) 8,074 0.5 (0.1)
Eub/Myun 3,417 0.9 (0.3)* 1,578 0.9 (0.3)* 1,839 0.9 (0.4)*
Income (standardized)
Low 4,277 0.6 (0.1) 1,895 0.5 (0.1)* 2,382 0.8 (0.2)*
Mid-low 4,455 0.6 (0.1) 1,984 0.5 (0.1)* 2,471 0.6 (0.1)
Mid-high 4,442 0.6 (0.1) 1,954 0.5 (0.2)* 2,488 0.7 (0.2)*
High 4,437 0.4 (0.1) 1,952 0.4 (0.1)* 2,485 0.5 (0.1)*
*Reconstructed from table 3-29 of National Health Statistics 2014.
Table 2. Report of hepatitis C by the sample surveillance within the last 4 years14 
Years
Cases of hepatitis C 
Total Male Female
2013 3,703 1,832 1,871
2014 4,126 2,043 2,083
2015 4,609 2,217 2,392
2016 (up to August) 4,003 1,911 2,092
Figure 2. Status of reporting of hepatitis C virus infection by year ac-
cording to sample surveillance.15
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severity of hemophilia.24 In their 2012 annual report, the Korea 
Hemophilia Foundation reported that the rates of anti-HCV anti-
body positivity and HCV RNA positivity were 20.0% and 5.5%, 
respectively.25 The anti-HCV prevalence tested by second-genera-
tion EIA was 67.7% in 1997; 82% of these individuals were im-
munoblot-positive.26 According to 2009 data, the anti-HCV preva-
lence and the HCV RNA positivity rate among those anti-HCV 
positive were 35.1% and 88%, respectively.27
Strategies for HCV control in South Korea 
As seen in the recent ‘HCV infection events’ in the Dana and 
Hanyang clinics, there is a problem with the management and in-
spection of the risk of viral hepatitis transmission in front-line 
medical institutes. Unlike hepatitis B, hepatitis C can be cured by 
antiviral treatment, and the sustained virologic response rate of 
this treatment is very high with few side-effects. Therefore, in Ko-
rea, if suspected, a hepatitis C test should be performed and 
treated early. Therefore, it is necessary to evaluate the national 
management system for hepatitis C, and a system of detection 
and reporting similar to those implemented by advanced countries 
should be developed.
At present, 186 medical institutions subject to the government’s 
selected monitoring are obliged to report cases of HCV to health 
authorities (Table 3). Therefore, HCV cases in medical institutes 
other than the 186 designated institutes can be missed. In No-
vember 2016, a new law which designated hepatitis C as a group 
3 nationally notifiable infectious disease and mandated a total re-
por ting system for HCV infection had been passed. This 
new law will come into effect on June. 3rd in 2017.
National screening for HCV infection has not yet been imple-
mented in South Korea, because its prevalence is relatively low 
compared to that of HBV infection. In contrast to HBV infection, 
HCV infection can be cured by administration of  direct acting an-
tivirals. Therefore, scholars believe that a national screening pro-
gram for HCV should be implemented to facilitate prompt treat-
ment. From the viewpoint of health economics, early treatment of 
HCV infection prior to progression of liver disease might reduce 
Table 3. The number of medical institutes obliged to report cases of HCV infection to health authorities and the number of the cases15
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
No. of medical institutes 677 728 788 833 877 873 889 1,035 1,024 167 170 167 175
No. of cases 1,927 2,033 1,657 2,843 4,401 5,179 6,407 6,406 5,629 4,316 4,272 3,703 4,126
Figure 3. The relationship between the cost-effectiveness of screening and treatment, the prevalence of HCV amongst the general population and 
the rate of therapy uptake post diagnosis.28
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the overall medical cost. One recent study used Markov modeling 
to assess the cost-effectiveness of antiviral treatment for patients 
in the general population diagnosed with hepatitis C.28 In that 
study, regardless of risk factors, hepatitis screening tests for HCV 
in 40-, 50-, and 60-year-olds reduced the incidence of liver cir-
rhosis and liver cancer by inhibiting the progression of liver dis-
ease. One-time HCV screening and treatment in South Koreans 
aged 40–70 years is likely to be highly cost-effective compared to 
the current practice not conducting screening.28 Screening result-
ed in the identification of 43,635 previously undiagnosed patients 
across all cohorts. One-time HCV screening and treatment was 
estimated to be cost-effective across all cohorts, and predicted 
incremental cost-effectiveness ratios (ICERs) ranged from $5,714 
to $8,889 per quality-adjusted life year (QALY) gained. Incremen-
tal costs associated with screening, treatment, and disease man-
agement ranged from $156.47 to $181.85 million USD; lifetime 
costs-offsets associated with the avoidance of end-stage liver dis-
ease complications ranged from $51.47 to $57.48 million USD.28 
The relationship among HCV prevalence, treatment uptake, and 
the cost-effectiveness of the screening and treatment program is 
shown in Fig. 3. Screening and treatment remained cost-effective 
at a $27,512/QALY threshold across all scenarios in which HCV 
prevalence was at least 0.04%. In the analysis using baseline HCV 
prevalence, screening remained cost-effective when treatment 
uptake was at least 11%, 12%, and 15% in the 40–49-year-old, 
50–59-year-old, and 60–69-year-old cohorts, respectively. The 
relationship between the timing of treatment after diagnosis and 
its incremental costs and QALY gains is presented in Table 4. 
Across all scenarios, treating patients sooner after diagnosis was 
associated with reduced total cost and increased QALY gains 
compared to base case analyses in which patients were treated 
over a 5-year time horizon. Decreasing the delay before treatment 
initiation increased cost-effectiveness estimates across all age 
groups.
Unlike Western countries, in which the major transmission route 
is illegal IV drug use, the prevalence of hepatitis C in South Korea 
is high in the elderly population, especially in coastal areas.8 Addi-
tionally, the frequencies of a history of acupuncture, moxibustion, 
and tattooing were higher in patients with hepatitis C. Moreover, 
workers in dental clinics, Oriental clinics, acupuncture centers, 
and tattoo parlors had low levels of awareness of infection con-
trol and are not obliged to report HCV infection. In the past 2 
years, the media has reported three outbreaks of infectious dis-
eases originating in medical institutions. Such outbreaks are pre-
sumed to be due to syringe reuse. Therefore, members of the 
general population who do not have high-risk diseases (including 
HIV, hemophilia, leprosy, and chronic kidney disease) could be ex-
posed to HCV infection in medical institutions in which invasive 
procedures are performed. Therefore, practical measures for in-
fection control should be implemented in these institutes. Also, 
appropriate supervision by health authorities of medical institu-
tions in which invasive procedures are performed is warranted. 
Education programs regarding the medical hazards of CHC and 
how to prevent transmission are necessary not only for the gener-
Table 4. The relationship between the timing of treatment post-diagnosis and the cost-effectiveness of a screening and treatment program28
Incremental results
(versus no screening and treatment)
Costs ($USD, million) QALYs ICER ($USD/QALY)
Scenario 1 (Age 40–49)
Base case 164.72 28,830 5,714
Treatment initiated over 3 years post-diagnosis 163.91 29,641 5,530
Treatment initiated in first year post-diagnosis 162.70 30,875 5,270
Scenario 2 (Age 50–59)
Base case 156.47 22,865 6,843
Treatment initiated over 3 years post-diagnosis 155.73 23,577 6,605
Treatment initiated in first year post-diagnosis 154.63 24,674 6,267
Scenario 3 (Age 60–69)
Base case 181.85 20,457 8,889
Treatment initiated over 3 years post-diagnosis 181.06 21,202 8,540
Treatment initiated in first year post-diagnosis 179.87 22,375 8,039
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; USD, United States Dollar.
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al population but also for medical personnel, including physicians 
and paramedics. 
Furthermore, establishment of an independent ‘viral hepatitis 
sector’ in Korea Center for Disease Control & Prevention is recom-
mended to implement a strategy for the management of viral 
hepatitis. As a control tower has paramount importance in provid-
ing health care strategy into practice, organization of an ‘integrat-
ed national viral hepatitis control system’ is proposed.
CONCLUSION
As no vaccine against HCV is available, HCV management in-
volves blocking routes of transmission, screening for HCV infec-
tion, and preventing liver disease progression by treatment. Highly 
potent oral direct antiviral agents are now available. Therefore, 
early detection through national screening and appropriate treat-
ment should be implemented to improve the quality of life of pa-
tients with HCV.
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